1. Home
  2. ORKA vs ADV Comparison

ORKA vs ADV Comparison

Compare ORKA & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

N/A

Current Price

$95.72

Market Cap

6.4B

Sector

Health Care

ML Signal

N/A

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

N/A

Current Price

$24.64

Market Cap

410.7M

ML Signal

N/A

Company Overview

Basic Information
Metric
ORKA
ADV
Founded
2004
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
410.7M
IPO Year
1997
2019

Fundamental Metrics

Financial Performance
Metric
ORKA
ADV
Price
$95.72
$24.64
Analyst Decision
Strong Buy
Buy
Analyst Count
13
2
Target Price
★ $156.17
$42.50
AVG Volume (30 Days)
★ 904.3K
75.3K
Earning Date
11-09-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $3,542,642,000.00
Revenue This Year
N/A
$1.41
Revenue Next Year
N/A
$1.27
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$25.23
$0.49
52 Week High
$115.52
$47.45

Technical Indicators

Market Signals
Indicator
ORKA
ADV
Relative Strength Index (RSI) 48.38 37.89
Support Level $94.05 $0.49
Resistance Level $95.83 $34.29
Average True Range (ATR) 6.23 3.77
MACD -1.19 -0.75
Stochastic Oscillator 6.57 5.16

Price Performance

Historical Comparison
ORKA
ADV

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

Share on Social Networks: